1el-Ebiary M, Tones A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, nonneutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med,1997,156(2 Pt 1) :583-590.
2Rello J,Esandi ME, Diaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest,1998,114: 146-149.
3Barenfanger J, Arakere P, Cruz RD, et al. Improved outcomes associated with limiting identification of Candida spp. in respiratory secretions. J Clin Microbiol,2003,41:5645-5649.
4Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplant,2002,30 : 931 -935.
5Uffredi ML, Mangiapan G, Cadranel J, et al. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis,2003,22:457-462.
6Perfect JR,Cox GM,Lee JY,et al. The impact of cultUre isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis,2001,33 : 1824-1833.
7Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with thempeutic response among patients with candidemia. Antimicrob Agents Chemother, 2005,49 :3171-3177.
8Latin RA,Bauer M,Thomas AM,et al. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob Agents Chemother,2005,49:3297-3301.
9Rex JH, PfaUer MA, Walsh TJ, et al. Antifungal susceptibility testing:practical aspects and current challenges. Clin Microbiol Rev,2001,14:643-658.
10Matar MJ, Ostrosky-Zeichner L, Paetznick VL, et al. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.Antimicrob Agents Chemother,2003,47 : 1647-1651.
